Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (9712)	4/25/1999 9:41:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Lacking the facts of the particular case, it has been reported that new testing methods in the u.k. allow determination of meningococcemia even when antibiotics are given. In any case BPI is not considered an antibiotic. antibiotics are part of the standard treatment for meningococcemia but by eliminating bacteria they used to obscure the results. I remember a post by Cacacito that pointed out that the 80 or 85% confirmed m.n. bacteria in the open label trial was a high number and normally not seen due to the the issue mentioned above.

To: Arthur Radley who wrote (9712)	4/26/1999 11:47:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

March 9. "Nonetheless, we believe that we are now close to reaching the specified number, allowing us to conclude accrual with the statistical power called for in our trial design." April 9. Closer? May 9. ???????